Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum GB Group Ord Shs GBGPF

GB Group plc is a United Kingdom-based company, which provides identity data intelligence products and services helping organizations recognize and verify all elements of an individual's identity at key interactions in their business processes. The Company's segments include location, identity and fraud. The location segment includes address lookup, verification and capture; e-mail validation... see more

OTCPK:GBGPF - Post Discussion

GB Group Ord Shs > Big news!
View:
Post by Bobthebuilddr on Mar 02, 2017 8:51am

Big news!

CanniMed Therapeutics Inc. (TSX:CMED) ("CanniMed") and PharmaChoice today signed a letter of intent to collaborate on pharmacist education and the distribution, sale and marketing of medical cannabis products. This Smart News Release features multimedia. View the full release here: https://www.businesswire.com/news/home/20170302005765/en/ This industry-leading collaboration will see CanniMed responsible for producing and delivering accredited pharmacy education programs to PharmaChoice pharmacists and pharmacy technicians across Canada. In addition, CanniMed and PharmaChoice intend to enter a definitive agreement for distribution of medical cannabis through PharmaChoice pharmacists in Canada upon completion of the first provincial legislation change that allows such distribution. "We are pleased that PharmaChoice recognizes the value of CanniMed's core focus on professional education, our ability to produce standardized medical cannabis products in compliance with the government's Good Manufacturing Practice standards, and our manufacturing capabilities to provide reliably safe products for our patients," said Brent Zettl, President and CEO of CanniMed. "We believe that our industry is at the cusp of an important shift that will expand the role of pharmacists in counselling patients and dispensing medical cannabis products." PharmaChoice West CEO, Grady Brown, says that the dispensing of medical cannabis in Canadian pharmacies is a major step forward in Canada's healthcare landscape. "We recognize the incredible value medical cannabis has had on the lives of Canadians who have been prescribed the drug and found success in the therapy," says Brown. "It's important that we are well prepared to assist patients in achieving their therapeutic goals within the medical cannabis arena." PharmaChoice East CEO, Calvin LeRoux, echoes Brown's remarks in highlighting the critical due diligence required in selecting the right partner to prepare the banner's 700-plus independent pharmacies for the anticipated legislation. "We are extremely pleased with the industry-leading research and science that CanniMed offers," says LeRoux. "The professional education opportunities and programs they will provide to our members is precisely the specialized approach and leadership we were seeking." The definitive agreement between CanniMed and PharmaChoice will provide for PharmaChoice to distribute CanniMed products exclusively in exchange for CanniMed providing training programs for PharmaChoice pharmacists and pharmacy technicians. The definitive agreement will be completed within 60 days of the first legislation change that allows pharmacies to distribute medical cannabis.
Comment by Leafs420 on Mar 02, 2017 9:18am
great news!   I love how thinly traded CMED is... could be a good day once word gets out.  Dont need much volume to move this SP
Comment by Bobthebuilddr on Mar 02, 2017 9:20am
The funny thing is that loser Brent, follows me around like herpies and 1 stars all my posts. How can a copy and paste off a news release get a 1 star? Losers will be losers
Comment by SJSilver on Mar 02, 2017 9:36am
I agree with you Leafs, a great stock with a tight float like this is probably the most satisfying to take part in.
Comment by The6Kid on Mar 02, 2017 10:06am
To put things in perspective lets look at # of pharmacy locations: Shopper's Drug Mart: ~1307 Rexall: ~460 Pharmachoice: ~700
Comment by LettinPoniesRun on Mar 02, 2017 10:11am
Thank-you for the perspective,.. When you put it that way exclusive intent is interesting considering Shopper's isn't included...
Comment by EnglishTickler on Mar 02, 2017 10:26am
Does anyone know the exclusive details??? This sounds unreal for CMED... Pharmasave will only sell CanniMed product in exchange for staff training/education. The article doesn't say anything about CMED being exclusive to Pharmasave!!!
Comment by LettinPoniesRun on Mar 02, 2017 10:43am
PharmaChoice*  Keep it straight there tickles...
Comment by Bobthebuilddr on Mar 04, 2017 3:06pm
Did you even read the news release at all? For 1: it's PharmaChoice. Not pharma save. 2: it says exclusive right at the bottom as I'm sure you saw and are just being another ignorant stockhouse troll hoping to create confusion to get in a penny cheaper.
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities